EBV

pubmed: epstein barr and ste...
NCBI: db=pubmed; Term=epstein barr and stem cell therapy
NCBI pubmed
  • Preemptive therapy with rituximab for Epstein-Barr virus reactivation after haplo-HSCT.

    Preemptive therapy with rituximab for Epstein-Barr virus reactivation after haplo-HSCT.

    Pediatr Int. 2017 Jun 05;:

    Authors: Kobayashi S, Sano H, Mochizuki K, Ohara Y, Takahashi N, Ohto H, Kikuta A

    Abstract
    BACKGROUND: Epstein-Barr virus-related post-transplantation lymphoproliferative disorder (EBV-PTLD) is a serious complication in hematopoietic stem cell transplantation (HSCT) recipients.
    METHODS: We conducted a retrospective study to investigate the incidence and potential risk factors for EBV reactivation and to assess the efficacy of the management of EBV reactivation with preemptive rituximab in children who had T-cell-replete haploidentical HSCT (TCR-haplo-SCT) with low-dose anti-thymocyte globulin (ATG). EBV-DNA level in peripheral blood (PB) was determined when suspicious symptoms of EBV reactivation were observed. When the EBV-DNA level in PB increased to >1,000 copies/10(6) peripheral blood mononuclear cells (PBMCs), patients were preemptively treated with rituximab (375 mg/m(2) /dose).
    RESULTS: A total of 19 (50%) of 38 patients received rituximab infusion at a median time of 56 days after HSCT (range, 17-270). The median viral load at initiation of therapy was 2900 copies/10(6) PBMCs (range: 1000-650000). Preemptive therapy was started after a median of 2 (range, 0-7) days. The median number of weekly treatment cycles was 2 (range, 1-3). None of the patients developed PTLD or other EBV-associated diseases.
    CONCLUSION: We conclude that preemptive rituximab therapy could be a useful strategy for EBV-PTLD in TCR-haplo-SCT recipients with low-dose ATG. This article is protected by copyright. All rights reserved.

    PMID: 28581032 [PubMed - as supplied by publisher]

pubmed: epstein barr and ste...
NCBI: db=pubmed; Term=epstein barr and stem cell treatment
NCBI pubmed
  • Are the Polyomaviruses BK and JC Associated with Opportunistic Infections, Graft-versus-Host Disease, or Worse Outcomes in Adult Patients Receiving Their First Allogeneic Stem Cell Transplantation with Low-Dose Alemtuzumab?
    Related Articles

    Are the Polyomaviruses BK and JC Associated with Opportunistic Infections, Graft-versus-Host Disease, or Worse Outcomes in Adult Patients Receiving Their First Allogeneic Stem Cell Transplantation with Low-Dose Alemtuzumab?

    Acta Haematol. 2017 Jun 08;138(1):3-9

    Authors: Schneidewind L, Neumann T, Knoll F, Zimmermann K, Smola S, Schmidt CA, Krüger W

    Abstract
    BACKGROUND: The association of polyomaviruses BK and JC with other opportunistic infections and graft-versus-host disease (GvHD) in allogeneic stem cell transplantation is controversially discussed.
    METHODS: We conducted a retrospective study of 64 adult patients who received their first allogeneic stem cell transplantation between March 2010 and December 2014; the follow-up time was 2 years.
    RESULTS: Acute leukemia was the most frequent underlying disease (45.3%), and conditioning included myeloablative (67.2%) and nonmyeloablative protocols (32.8%). All patients received 10 mg of alemtuzumab on day -2 (20 mg in case of mismatch) as GvHD prophylaxis. Twenty-seven patients (41.5%) developed cytomegalovirus (CMV) reactivation. BKPyV-associated hemorrhagic cystitis was diagnosed in 10 patients (15.6%). Other opportunistic infections caused by viruses or protozoa occurred rarely (<10%). There was no association of BKPyV or JCPyV with CMV reactivation, Epstein-Barr virus reactivation, human herpes virus 6, or parvovirus B19 infection requiring treatment. There was a significant correlation of BKPyV-associated hemorrhagic cystitis with toxoplasmosis (p = 0.013). Additionally, there was a significant link of simultaneous BKPyV and JCPyV viruria with toxoplasmosis (p = 0.047). BKPyV and JCPyV were not associated with GvHD, relapse, or death.
    CONCLUSION: We found no association of BKPyV or JCPyV with viral infections or GvHD. Only the correlation of both polyomaviruses with toxoplasmosis was significant. This is a novel and interesting finding.

    PMID: 28591758 [PubMed - as supplied by publisher]